Follow
Navid Sobhani
Title
Cited by
Cited by
Year
CTLA-4 in regulatory T cells for cancer immunotherapy
N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li
Cancers 13 (6), 1440, 2021
2252021
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
N Sobhani, A D’Angelo, M Pittacolo, G Roviello, A Miccoli, SP Corona, ...
Cells 8 (4), 321, 2019
1502019
The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis
N Sobhani, G Roviello, SP Corona, M Scaltriti, A Ianza, M Bortul, ...
Journal of cellular biochemistry 119 (6), 4287-4292, 2018
1212018
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
GR Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta ...
Cancers 12 (11), E3293, 2020
822020
The fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments
N Sobhani, C Fan, P O. Flores-Villanueva, D Generali, Y Li
International journal of molecular sciences 21 (6), 2011, 2020
642020
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
N Sobhani, B Scaggiante, R Morris, D Chai, M Catalano, DR Tardiel-Cyril, ...
Cancer treatment reviews 109, 102429, 2022
572022
AR-V7 in metastatic prostate cancer: a strategy beyond redemption
N Sobhani, PK Neeli, A D’angelo, M Pittacolo, M Sirico, IC Galli, ...
International journal of molecular sciences 22 (11), 5515, 2021
542021
Cancer/testis antigens: from serology to mRNA cancer vaccine
C Fan, H Qu, X Wang, N Sobhani, L Wang, S Liu, W Xiong, Z Zeng, Y Li
Seminars in cancer biology 76, 218-231, 2021
512021
Advances in systemic therapy for metastatic breast cancer: future perspectives
SP Corona, N Sobhani, A Ianza, G Roviello, G Mustacchi, M Bortul, ...
Medical oncology 34, 1-16, 2017
492017
Current status of fibroblast growth factor receptor-targeted therapies in breast cancer
N Sobhani, A Ianza, A D’angelo, G Roviello, F Giudici, M Bortul, ...
Cells 7 (7), 76, 2018
452018
Advances in anti-BRAF therapies for lung cancer
G Roviello, A D’Angelo, M Sirico, M Pittacolo, FU Conter, N Sobhani
Investigational New Drugs 39 (3), 879-890, 2021
402021
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?
N Sobhani, D Generali, F Zanconati, M Bortul, B Scaggiante
World journal of clinical oncology 9 (2), 26, 2018
402018
The Next-generation DNA Vaccine Platforms and Delivery Systems: Advances, Challenges and Prospects
B Lu, JM Lim, B Yu, SY Song, P Neeli, N Sobhani, SR Bonam, ...
Frontiers in Immunology 15, 1332939, 2024
392024
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
N Sobhani, A Fassl, G Mondani, D Generali, T Otto
Cells 10 (2), 293, 2021
392021
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
A D’Angelo, N Sobhani, G Roviello, S Bagby, D Bonazza, C Bottin, ...
PLoS One 14 (8), e0219566, 2019
362019
Mutant p53 as an antigen in cancer immunotherapy
N Sobhani, A D’angelo, X Wang, KH Young, D Generali, Y Li
International journal of molecular sciences 21 (11), 4087, 2020
312020
Lenvatinib for the treatment of renal cell carcinoma
G Roviello, SP Corona, G Bozza, M Aieta, D Generali, MG Rodriquenz, ...
Expert Opinion on Investigational Drugs 27 (5), 507-512, 2018
282018
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
R Roudi, A D'Angelo, M Sirico, N Sobhani
International Immunopharmacology 101, 108322, 2021
232021
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer
N Sobhani, D Generali, A D’Angelo, M Aieta, G Roviello
Investigational new drugs 36 (6), 1133-1137, 2018
232018
The role of genomics and proteomics in lung cancer early detection and treatment
MH Abbasian, AM Ardekani, N Sobhani, R Roudi
Cancers 14 (20), 5144, 2022
212022
The system can't perform the operation now. Try again later.
Articles 1–20